Furthermore, we found a nearly statistically significant increase in the overall NSCLC risk for the rs12914385 (CHRNA3) C/T polymorphic variation (OR = 1.835, 95% CI: 0.964–3.490) when compared with the rs12914385 (CHRNA3) C/C variant(Table 3). This evidence concerns the gene CHRNA3 and non-small cell lung carcinoma.